Delayed
Japan Exchange
11:30:00 01/07/2024 am IST
|
5-day change
|
1st Jan Change
|
512
JPY
|
-5.36%
|
|
-6.48%
|
+48.62%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,850
|
2,047
|
1,708
|
2,045
|
3,060
|
-
|
-
|
Enterprise Value (EV)
1 |
4,079
|
1,925
|
3,157
|
3,651
|
3,060
|
3,060
|
3,060
|
P/E ratio
|
22.4
x
|
10.1
x
|
14.9
x
|
18.4
x
|
24.5
x
|
17
x
|
14.2
x
|
Yield
|
1.62%
|
3.12%
|
3.14%
|
2.61%
|
1.76%
|
1.76%
|
2.15%
|
Capitalization / Revenue
|
0.75
x
|
0.41
x
|
0.26
x
|
0.29
x
|
0.33
x
|
0.29
x
|
0.26
x
|
EV / Revenue
|
0.75
x
|
0.41
x
|
0.26
x
|
0.29
x
|
0.33
x
|
0.29
x
|
0.26
x
|
EV / EBITDA
|
1,24,73,207
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-2,56,67,948
x
|
-
|
-20,73,065
x
|
50,86,999
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-0%
|
0%
|
-
|
-
|
-
|
Price to Book
|
3.31
x
|
1.55
x
|
1.09
x
|
1.26
x
|
1.8
x
|
1.67
x
|
1.55
x
|
Nbr of stocks (in thousands)
|
5,816
|
5,934
|
5,952
|
5,936
|
5,976
|
-
|
-
|
Reference price
2 |
662.0
|
345.0
|
287.0
|
344.5
|
512.0
|
512.0
|
512.0
|
Announcement Date
|
12/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
5,110
|
5,029
|
6,638
|
7,087
|
9,227
|
10,477
|
11,620
|
EBITDA
|
308.7
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
295
|
251
|
167
|
172
|
277
|
340
|
399
|
Operating Margin
|
5.77%
|
4.99%
|
2.52%
|
2.43%
|
3%
|
3.25%
|
3.43%
|
Earnings before Tax (EBT)
|
255
|
266
|
201
|
161
|
-
|
-
|
-
|
Net income
1 |
155
|
200
|
114
|
111
|
125
|
180
|
215
|
Net margin
|
3.03%
|
3.98%
|
1.72%
|
1.57%
|
1.35%
|
1.72%
|
1.85%
|
EPS
2 |
29.61
|
34.18
|
19.26
|
18.74
|
20.90
|
30.15
|
36.00
|
Free Cash Flow
|
-150
|
-
|
-824
|
402
|
-
|
-
|
-
|
FCF margin
|
-2.94%
|
-
|
-12.41%
|
5.67%
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
362.16%
|
-
|
-
|
-
|
Dividend per Share
2 |
10.70
|
10.75
|
9.000
|
9.000
|
9.000
|
9.000
|
11.00
|
Announcement Date
|
12/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
---|
Net sales
1 |
2,405
|
1,027
|
2,883
|
1,624
|
1,347
|
3,376
|
1,586
|
1,651
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
91
|
-82
|
25
|
-4
|
-38
|
136
|
-28
|
-183
|
Operating Margin
|
3.78%
|
-7.98%
|
0.87%
|
-0.25%
|
-2.82%
|
4.03%
|
-1.77%
|
-11.08%
|
Earnings before Tax (EBT)
1 |
99
|
-99
|
33
|
5
|
-41
|
120
|
-31
|
-181
|
Net income
1 |
57
|
-68
|
5
|
-6
|
-25
|
69
|
-30
|
-143
|
Net margin
|
2.37%
|
-6.62%
|
0.17%
|
-0.37%
|
-1.86%
|
2.04%
|
-1.89%
|
-8.66%
|
EPS
2 |
9.920
|
-11.48
|
0.9650
|
-1.145
|
-4.260
|
11.68
|
-5.005
|
-24.15
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/08/21
|
13/05/22
|
09/08/22
|
14/11/22
|
15/05/23
|
09/08/23
|
14/11/23
|
15/05/24
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
229
|
-
|
1,449
|
1,606
|
-
|
-
|
-
|
Net Cash position
|
-
|
122
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.7419
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-150
|
-
|
-824
|
402
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
16.8%
|
16.1%
|
7.9%
|
13.7%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
8.69%
|
4.85%
|
2.97%
|
-
|
-
|
-
|
Assets
1 |
-
|
2,301
|
2,353
|
3,734
|
-
|
-
|
-
|
Book Value Per Share
2 |
200.0
|
223.0
|
264.0
|
274.0
|
285.0
|
306.0
|
331.0
|
Cash Flow per Share
|
32.00
|
36.00
|
30.10
|
31.80
|
-
|
-
|
-
|
Capex
|
-
|
26
|
25
|
12
|
-
|
-
|
-
|
Capex / Sales
|
-
|
0.52%
|
0.38%
|
0.17%
|
-
|
-
|
-
|
Announcement Date
|
12/02/21
|
15/02/22
|
14/02/23
|
13/02/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +48.62% | 20.1M | | +56.86% | 815B | | +43.90% | 641B | | -6.57% | 352B | | +17.32% | 314B | | +9.94% | 303B | | +16.08% | 242B | | +2.29% | 224B | | +13.96% | 218B | | +7.98% | 168B |
Other Pharmaceuticals
|